Industry News
Cambrex increases flexible manufacturing capacity at Karlskoga facility
U
S-headquartered pharmaceutical CDMO Cambrex is investing $3.6 million at its Karlskoga,
Sweden facility to increase flexible drug substance manufacturing capacity. The work, which will convert a previously customer- dedicated manufacturing train, will include an additional production line at 6 cubic metre scale being added at the site resulting in a 25 per cent capacity increase at the facility. Engineering work for the
expansion has already commenced at the facility and is expected to be completed by November this year. The work involves modification of an existing four-reactor configuration and the installation of
Cambrex: investing in added flexible manufacturing capacity at its Karlskoga facility in Sweden.
new holding tanks and a 4 square metre Hastelloy Rosemund filter. “We are seeing continued
growth in commercial-scale API manufacturing, and an ongoing trend for customers favouring high-
quality European and US partners, so we must ensure capacity is both flexible and available to be in a position to react quickly and effectively to customers’ changing requirements,” commented
Bjarne Sandberg, Managing Director, Cambrex Karlskoga. “This investment, as with others made by Cambrex across our global network, is in line with the company strategy of ensuring that the assets we can offer customers allow for the most cost-effective and efficient manufacturing.” Cambrex’s site in Karlskoga employs more than 400 people and features a wide range of flexible manufacturing facilities, including four cGMP pilot plants and five full- scale commercial production units. In 2019, a new 600 sqare metre process and analytical development facility was added to the site, along with a 3,000 square metre logistics centre.
Piramal Pharma Solutions acquires solid dose facility
BASF working toward circularity
in recycling of mattresses BASF has developed a chemical recycling process for used mattresses and is starting pilot tests at the company’s Schwarzheide site in Brandenburg, Germany. The materials from old mattresses are to be recycled in such a way that they can be used for the production of new mattresses. “The target is to recover the raw materials with a quality comparable to that of non- recycled/virgin raw materials”, said Shankara Keelapandal, Business Management Isocyanates Europe. The company says it is breaking
6
new ground and responding to the raised expectations regarding sustainability of the foam and mattress industry as well as those of consumers and that this is an important step to possibly re-enter post-consumer waste back into product lifecycles. BASF’s process breaks down the flexible polyurethane and delivers the initially used polyol. From there the company can produce new foam with a significantly lower carbon footprint, because fewer fossil resources are used.
from G&W Laboratories Inc Piramal Enterprises Limited’s Pharma Solutions (PPS) has entered into an agreement with G&W Laboratories Inc. to acquire G&W’s solid oral dosage drug product manufacturing facility in Sellersville, Pennsylvania. Under the agreement, PEL, through one of its affiliates, would acquire at closing a 100 per cent stake in the entity that operates the facility and owns the related real estate. The acquisition will add solid oral
dosage form capabilities in North America to PPS’s manufacturing portfolio: until now, the company’s
capabilities in solid oral dosage forms were all located in the UK and India. The Sellersville site can also produce liquids, creams, and ointments, further expanding the PPS portfolio and the site also can support product and process development for solid oral dosage and oral liquids, including immediate release, modified release, chewable and sublingual solid oral dosage forms, solutions and suspensions in liquids. The site has received certifications from the FDA and the EMA.
www.chemicalsknowledgehub.com
G&W Laboratories’ Sellersville, Pennsylvania facility in the US will shortly be acquired by Piramal Pharma.
Summer 2020
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
